Valuable Targets

Progress in the Research of Heparin antagonists

21 September 2023
4 min read

Heparin is a naturally occurring anticoagulant that plays a crucial role in the human body's blood clotting process. It is primarily produced by mast cells and acts by inhibiting the activity of various clotting factors, particularly thrombin and factor Xa. Heparin prevents the formation of blood clots by interfering with the conversion of fibrinogen to fibrin, which is essential for clot formation. This mechanism makes heparin an essential medication for preventing and treating conditions such as deep vein thrombosis, pulmonary embolism, and during certain surgical procedures. Additionally, heparin is also used in laboratory settings for various diagnostic tests related to blood clotting disorders.

Heparin Competitive Landscape

According to the data provided by Patsnap Synapse-Global Drug Intelligence Database: the following figure shows that as of 18 Sep 2023, there are a total of 12 Heparin drugs worldwide, from 19 organizations, covering 18 indications, and conducting 21 clinical trials.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target.

Based on the analysis of the provided data, the current competitive landscape of target Heparin shows that Dilafor AB, Modus Therapeutics Holding AB, and Lee's Pharmaceutical Holdings Ltd. are the companies growing the fastest. The highest stage of development is Phase 2, with small molecule drugs being the most rapidly progressing drug type. 

The indications being explored include various diseases and conditions, but no drugs have been approved yet. The European Union, Sweden, Finland, and Italy are the countries/locations developing fastest under the current target.

Overall, the future development of target Heparin shows potential for advancements in the treatment of various indications, with a focus on small molecule drugs and ongoing research and development efforts by key companies.

Key Drug: Delparantag

Delparantag is a small molecule drug that was developed by Cellceutix Pharma, Inc. It was designed to target heparin, a commonly used anticoagulant medication. The drug was intended to be used in the treatment of cardiovascular diseases and hemic and lymphatic diseases.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

 

However, despite its potential therapeutic applications, Delparantag did not progress beyond the highest phase of development and has been discontinued. The reasons for discontinuation are not provided in the given information, but it could be due to various factors such as lack of efficacy, safety concerns, or commercial viability.

As a small molecule drug, Delparantag is likely to have been developed through traditional drug discovery and development processes. Small molecule drugs are typically synthesized chemically and have a relatively low molecular weight, allowing them to be easily absorbed and distributed in the body. They often act by binding to specific targets, in this case, heparin, to exert their therapeutic effects.

The therapeutic areas of cardiovascular diseases and hemic and lymphatic diseases encompass a wide range of conditions affecting the heart, blood vessels, and blood cells. These diseases can include conditions such as heart failure, coronary artery disease, deep vein thrombosis, and various types of anemia. The development of drugs targeting these therapeutic areas is crucial for improving patient outcomes and addressing unmet medical needs.

Cellceutix Pharma, Inc. is the originator organization of Delparantag. Originator organizations are typically responsible for the initial discovery and development of a drug. They invest significant resources in preclinical and clinical studies to demonstrate the drug's safety and efficacy before seeking regulatory approval.

In summary, Delparantag is a small molecule drug developed by Cellceutix Pharma, Inc. that targets heparin. It was intended for use in the treatment of cardiovascular diseases and hemic and lymphatic diseases. However, the drug did not progress beyond the highest phase of development and has been discontinued. Further information regarding the reasons for discontinuation or any potential future developments is not provided.

图形用户界面, 文本

描述已自动生成

Orexo submits NDA for OX124 to FDA, a high-potency antidote for opioid overdose
Latest Hotspot
3 min read
Orexo submits NDA for OX124 to FDA, a high-potency antidote for opioid overdose
21 September 2023
Orexo AB recently submitted its NDA to the US FDA for OX124, a high-dose, nasally-administered treatment for opioid overdoses.
Read →
Medications intervening from the root of difficult and complex diseases: Oligonucleotides
Advanced Tech.
7 min read
Medications intervening from the root of difficult and complex diseases: Oligonucleotides
21 September 2023
Oligonucleotides (ONs) are a class of drugs composed of single or double strands of oligonucleotides synthesized by artificial chemistry.
Read →
Yescarta® Car T-cell therapy from Kite greatly boosts treatment response and prolongs remission in relapsed/resistant Large B-cell Lymphoma patients
Latest Hotspot
3 min read
Yescarta® Car T-cell therapy from Kite greatly boosts treatment response and prolongs remission in relapsed/resistant Large B-cell Lymphoma patients
21 September 2023
Kite's Car T-cell Therapy Yescarta® exhibits a substantial treatment response rate and durable remission for patients with relapsed/resistant Large B-cell Lymphoma.
Read →
Analysis on the Clinical Research Progress of CTLA-4 Inhibitors
Analysis on the Clinical Research Progress of CTLA-4 Inhibitors
21 September 2023
Cytotoxic T Lymphocyte-Associated Antigen-4 (CTLA-4), also known as CD152, is a transmembrane protein on the surface of T cells encoded by the CTLA-4 gene.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.